Cardiff Oncology (NASDAQ:CRDF) Given "Outperform" Rating at William Blair

Cardiff Oncology (NASDAQ:CRDF - Get Free Report)'s stock had its "outperform" rating reiterated by William Blair in a research note issued on Wednesday,RTT News reports.

Separately, HC Wainwright upped their price target on Cardiff Oncology from $17.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, May 9th.

Cardiff Oncology Trading Down 18.4%

Shares of NASDAQ:CRDF traded down $0.68 during midday trading on Wednesday, reaching $3.02. The company had a trading volume of 3,722,102 shares, compared to its average volume of 1,186,499. The company's 50 day moving average price is $3.06 and its 200 day moving average price is $3.54. The stock has a market cap of $200.92 million, a P/E ratio of -3.28 and a beta of 1.61. Cardiff Oncology has a 52-week low of $2.01 and a 52-week high of $5.64.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). The company had revenue of $0.11 million during the quarter, compared to analysts' expectations of $0.09 million. Cardiff Oncology had a negative return on equity of 76.45% and a negative net margin of 8,308.50%. Research analysts forecast that Cardiff Oncology will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Cardiff Oncology

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp increased its holdings in Cardiff Oncology by 68.7% in the 4th quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company's stock worth $1,253,000 after buying an additional 117,514 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in Cardiff Oncology by 73.7% in the 4th quarter. Nuveen Asset Management LLC now owns 586,616 shares of the company's stock worth $2,546,000 after buying an additional 248,850 shares in the last quarter. Laurion Capital Management LP bought a new stake in Cardiff Oncology in the 4th quarter worth about $2,504,000. American Century Companies Inc. increased its holdings in Cardiff Oncology by 12.8% in the 4th quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock worth $234,000 after buying an additional 6,140 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Cardiff Oncology by 8.9% in the 4th quarter. Northern Trust Corp now owns 337,092 shares of the company's stock worth $1,463,000 after buying an additional 27,489 shares in the last quarter. 16.29% of the stock is currently owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.